论文部分内容阅读
目的 探讨厄贝沙坦联合氢氯噻嗪治疗老年原发性高血压患者的效果。方法 老年原发性高血压患者126例,以随机数字表法分为A组、B组及C组,A组给予厄贝沙坦150 mg,1次/d,口服;B组给予氢氯噻嗪12.5 mg,1次/d,口服;C组给予厄贝沙坦+氢氯噻嗪,1次/d,口服;持续治疗2个月。比较治疗前后各组舒张压、收缩压及不良反应发生率。结果 与A、B组比较,C组治疗后收缩压、舒张压均低,差异有统计学意义(P均<0.05);C组不良反应总发生率为13.95%(6/43),A、B组分别为9.76%(4/41)、11.90%(5/42),各组比较,P>0.05。结论 厄贝沙坦联合氢氯噻嗪可降低老年原发性高血压患者血压水平,安全性高。
Objective To investigate the effect of irbesartan combined with hydrochlorothiazide in the treatment of elderly patients with essential hypertension. Methods A total of 126 elderly patients with essential hypertension were divided into groups A, B and C randomly by random number table. Group A received irbesartan 150 mg once a day for oral administration. Group B received hydrochlorothiazide 12.5 mg , Once a day, orally; Group C given irbesartan + hydrochlorothiazide, 1 / d, orally; sustained treatment for 2 months. The diastolic blood pressure, systolic blood pressure and incidence of adverse reactions in each group were compared before and after treatment. Results Compared with group A and group B, the systolic and diastolic blood pressures were lower in group C after treatment (P <0.05). The total incidence of adverse reactions in group C was 13.95% (6/43) B group was 9.76% (4/41) and 11.90% (5/42) respectively, P> 0.05. Conclusion Irbesartan combined with hydrochlorothiazide can reduce the blood pressure of elderly patients with essential hypertension, high safety.